

Aerolytica exists to transform how life-saving peptide and biologic medicines are delivered. By combining world-class pulmonary science, responsible commercialization, collaborative regulatory innovation, and partnerships that improve patient access, Aerolytica seeks to build a platform that creates enduring value for patients, healthcare systems, scientific collaborators, and investors alike. We believe that breakthrough innovation and broad access are complementary goals—and that a Public Benefit Corporation can responsibly pursue both.

Injectable and oral drug delivery remain the default — not because they're optimal, but because inhalation-based formulation has historically been difficult to de-risk.
The result is a massive gap: millions of patients managing chronic and acute conditions with delivery mechanisms that are slower, less efficient, and harder to tolerate than inhaled alternatives could be.
The global inhaled drug delivery market is projected to exceed $75 billion by 2030. Aerolytica is positioned at the leading edge of this shift by using AI to compress the formulation timeline and reduce development risk from the ground up.

Predictive modeling accelerates particle design and excipient selection, cutting early-stage timelines significantly.

Every indication is selected for its suitability to inhaled delivery — maximizing bioavailability and patient compliance.

Our AI-first methodology is built to produce new drug candidates at a fraction of traditional development cost.
We seek to leverage AI in two distinct embodiments. AI will provide valuable iterative input for research and development across all sectors of our system, while another AI engine will assist with dose delivery and monitoring of the patient condition.
A unique, proprietary drug delivery molecule is at the center of what we aim to achieve. We anticipate our approach will contribute towards providing greater medication adherence and reduce disease state complications.
The physical device in which we will package our AI-embedded drug delivery system will be state-of-the-art and is envisioned to possess integrated security features and communication capabilities to external biofeedback devices.

Chief Executive Officer

Chief Science Officer

Chief Clinical Officer

Chief Information Officer
© 2026 Aerolytica Pharma, Inc. All rights reserved. Denver, Colorado.
This website does not constitute an offer to sell or solicitation of an offer to buy securities.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.